Axiom-4 will carry the first FDA-approved cancer drug candidate into space to fast-track preclinical testing using patient-derived tumour models.
The Axiom-4 mission is set to launch a unique experiment in cancer research. The mission will carry Rebecsinib, a drug developed by Aspera Biomedicines that targets a gene known as ADAR1 – linked to cancer cloning and immune evasion. This will be the first time a drug with active FDA Investigational New Drug (IND) status is tested in microgravity conditions.
According to The Economic Times, Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute and founder of Aspera, explained that tumour organoids – miniature tumour models derived from patient cells – grow nearly twice as fast in space. This makes the space environment suitable for simulating aggressive cancer progression in a short timeframe. In earlier missions, Axiom-2 and Axiom-3, preliminary versions of the study were conducted. Axiom-4 builds on that work, focusing on how Rebecsinib performs across different tumour types.
The aim is to collect preclinical data that could speed up the identification of effective treatment pathways, especially for patients with fast-moving cancers. Since the organoids in microgravity replicate patient tumour behaviour more closely and quickly, researchers expect to generate insights faster than traditional lab settings on Earth. This could potentially improve the chances of success in future clinical trials.
